TY - JOUR
T1 - MELANOMA ADJUVANT TREATMENT
T2 - current insight and clinical features
AU - D Aniello, Carmine
AU - Scarpati, Giuseppina Della Vittoria
AU - Pepa, Chiara Della
AU - Pisconti, Salvatore
AU - Montesarchio, Vincenzo
AU - Wernert, Nicolas
AU - Zarone, Mayra Rachele
AU - Caraglia, Michele
AU - Facchini, Gaetano
AU - Cavaliere, Carla
N1 - Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
PY - 2018
Y1 - 2018
N2 - Melanoma represents 2-3% of all cancers, 95% of them arise from skin, while only 5% are non-cutaneous melanoma. Despite an optimal surgery management, the risk of a local and systemic relapse remains high, particularly in high-risk patients (node-positive or node-negative T3b, T4 a/b). We conducted a systematic review of the main published and ongoing phase I/II/III trials between 2000 and June 2015 on the adjuvant treatment of cutaneous melanoma. The IFN remains the only option currently available for this aim. Ipilimumab represents a possible breakthrough in this setting, considering the positive results of the EORTC 18701 trials in terms of disease free survival (DFS), while data regarding OS are pending. Recent advances in the understanding of the biology of melanoma result in the identification of MAPK pathway role in the melanoma development Based on these features, B-RAF inhibitors and their combination with immunotherapy could represent the upcoming therapeutic strategy.
AB - Melanoma represents 2-3% of all cancers, 95% of them arise from skin, while only 5% are non-cutaneous melanoma. Despite an optimal surgery management, the risk of a local and systemic relapse remains high, particularly in high-risk patients (node-positive or node-negative T3b, T4 a/b). We conducted a systematic review of the main published and ongoing phase I/II/III trials between 2000 and June 2015 on the adjuvant treatment of cutaneous melanoma. The IFN remains the only option currently available for this aim. Ipilimumab represents a possible breakthrough in this setting, considering the positive results of the EORTC 18701 trials in terms of disease free survival (DFS), while data regarding OS are pending. Recent advances in the understanding of the biology of melanoma result in the identification of MAPK pathway role in the melanoma development Based on these features, B-RAF inhibitors and their combination with immunotherapy could represent the upcoming therapeutic strategy.
U2 - 10.2174/1568009617666170208163714
DO - 10.2174/1568009617666170208163714
M3 - Article
C2 - 28183255
JO - Current Cancer Drug Targets
JF - Current Cancer Drug Targets
SN - 1568-0096
ER -